Persistence and adherence to biologic therapies in juvenile idiopathic arthritis

Abstract Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease that often requires biological therapy to control its activity. Medication persistence and adherence are important aspects on which we have scarce information. We performed a longitudinal, retrospective, and observational...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Juan Carlos Nieto-González, Laura Trives-Folguera, Alejandra Melgarejo-Ortuño, Aranzazu Ais, Belén Serrano-Benavente, María Sanjurjo, José María Álvaro-Gracia, Indalecio Monteagudo Sáez
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2d8239bb0ae3444ea771d572512aa78a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2d8239bb0ae3444ea771d572512aa78a
record_format	dspace
spelling	oai:doaj.org-article:2d8239bb0ae3444ea771d572512aa78a2021-12-02T18:50:47ZPersistence and adherence to biologic therapies in juvenile idiopathic arthritis10.1038/s41598-021-95252-82045-2322https://doaj.org/article/2d8239bb0ae3444ea771d572512aa78a2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95252-8https://doaj.org/toc/2045-2322Abstract Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease that often requires biological therapy to control its activity. Medication persistence and adherence are important aspects on which we have scarce information. We performed a longitudinal, retrospective, and observational study based on data from the daily clinical management of JIA patients. We recorded clinical remission at 6 and 12 months. Persistence of biological therapy was evaluated using Kaplan–Meier curves, and adherence was assessed using the medication possession ratio (MPR). We included 68 patients who received biological therapy. Of these, 11 (16.2%) and 5 (7.4%) required a second and third drug, respectively. The persistence rate for biological therapy at 5 years was 64%, with no differences between the first and second lines. Adherence was high during the first year of treatment (MPR80: 96.3%) and also in the second and third years (MPR80: 85.2% and 91.8%, respectively). Persistence and adherence to biological therapy were remarkably high in our JIA cohort. Adherence to biological treatments could be related to a higher probability of fulfilling the Wallace remission criteria at 6 months, although this was not confirmed at 12 months.Juan Carlos Nieto-GonzálezLaura Trives-FolgueraAlejandra Melgarejo-OrtuñoAranzazu AisBelén Serrano-BenaventeMaría SanjurjoJosé María Álvaro-GraciaIndalecio Monteagudo SáezNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Juan Carlos Nieto-González Laura Trives-Folguera Alejandra Melgarejo-Ortuño Aranzazu Ais Belén Serrano-Benavente María Sanjurjo José María Álvaro-Gracia Indalecio Monteagudo Sáez Persistence and adherence to biologic therapies in juvenile idiopathic arthritis
description	Abstract Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease that often requires biological therapy to control its activity. Medication persistence and adherence are important aspects on which we have scarce information. We performed a longitudinal, retrospective, and observational study based on data from the daily clinical management of JIA patients. We recorded clinical remission at 6 and 12 months. Persistence of biological therapy was evaluated using Kaplan–Meier curves, and adherence was assessed using the medication possession ratio (MPR). We included 68 patients who received biological therapy. Of these, 11 (16.2%) and 5 (7.4%) required a second and third drug, respectively. The persistence rate for biological therapy at 5 years was 64%, with no differences between the first and second lines. Adherence was high during the first year of treatment (MPR80: 96.3%) and also in the second and third years (MPR80: 85.2% and 91.8%, respectively). Persistence and adherence to biological therapy were remarkably high in our JIA cohort. Adherence to biological treatments could be related to a higher probability of fulfilling the Wallace remission criteria at 6 months, although this was not confirmed at 12 months.
format	article
author	Juan Carlos Nieto-González Laura Trives-Folguera Alejandra Melgarejo-Ortuño Aranzazu Ais Belén Serrano-Benavente María Sanjurjo José María Álvaro-Gracia Indalecio Monteagudo Sáez
author_facet	Juan Carlos Nieto-González Laura Trives-Folguera Alejandra Melgarejo-Ortuño Aranzazu Ais Belén Serrano-Benavente María Sanjurjo José María Álvaro-Gracia Indalecio Monteagudo Sáez
author_sort	Juan Carlos Nieto-González
title	Persistence and adherence to biologic therapies in juvenile idiopathic arthritis
title_short	Persistence and adherence to biologic therapies in juvenile idiopathic arthritis
title_full	Persistence and adherence to biologic therapies in juvenile idiopathic arthritis
title_fullStr	Persistence and adherence to biologic therapies in juvenile idiopathic arthritis
title_full_unstemmed	Persistence and adherence to biologic therapies in juvenile idiopathic arthritis
title_sort	persistence and adherence to biologic therapies in juvenile idiopathic arthritis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2d8239bb0ae3444ea771d572512aa78a
work_keys_str_mv	AT juancarlosnietogonzalez persistenceandadherencetobiologictherapiesinjuvenileidiopathicarthritis AT lauratrivesfolguera persistenceandadherencetobiologictherapiesinjuvenileidiopathicarthritis AT alejandramelgarejoortuno persistenceandadherencetobiologictherapiesinjuvenileidiopathicarthritis AT aranzazuais persistenceandadherencetobiologictherapiesinjuvenileidiopathicarthritis AT belenserranobenavente persistenceandadherencetobiologictherapiesinjuvenileidiopathicarthritis AT mariasanjurjo persistenceandadherencetobiologictherapiesinjuvenileidiopathicarthritis AT josemariaalvarogracia persistenceandadherencetobiologictherapiesinjuvenileidiopathicarthritis AT indaleciomonteagudosaez persistenceandadherencetobiologictherapiesinjuvenileidiopathicarthritis
_version_	1718377494480945152

Persistence and adherence to biologic therapies in juvenile idiopathic arthritis

Ejemplares similares